BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Cervical cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for cervical cancer: 521 (317 sponsors; 62 newly posted in the last 180 days, 24 stopped in the last 180 days; 31 new-entrant sponsors). Momentum score 9.6, rank 73 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 7, Phase 1 159, Phase 2 207, Phase 3 66, Phase 4 8, N/A 74.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 7 | P3 5, P2 2 | 3 | 0 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 27 | P2 15, P1 8, P3 4 | 5 | 10 |
| AstraZeneca AZN | 16 | P2 7, P3 4, NA 1, P1 4 | 0 | 3 |
| Akeso | 5 | P3 4, P2 1 | 0 | 2 |
| Merck Sharp & Dohme LLC MRK | 11 | P2 6, P4 1, P3 3, NA 1 | 1 | 1 |
| Exelixis EXEL | 6 | P3 2, P1 3, P4 1 | 0 | 2 |
| Genmab GMAB | 5 | P3 2, P2 3 | 0 | 0 |
| Lepu Biopharma Co., Ltd. | 4 | P2 2, P3 2 | 0 | 0 |
| Rakuten Medical, Inc. | 3 | P3 2, P2 1 | 0 | 0 |
| MediLink Therapeutics (Suzhou) Co., Ltd. | 4 | P2 3, P3 1 | 0 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 4 | P3 1, P2 3 | 0 | 1 |
| Bicara Therapeutics BCAX | 3 | P2 1, P3 1, P1 1 | 1 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | P2 1, NA 1, P3 1 | 0 | 2 |
| Daiichi Sankyo | 3 | P3 1, P2 2 | 0 | 0 |
| GlaxoSmithKline | 3 | P3 1, P1 1, P2 1 | 0 | 0 |
| Hansoh BioMedical R&D Company | 3 | P2 2, P3 1 | 1 | 0 |
| Jazz Pharmaceuticals JAZZ | 3 | P3 1, NA 1, P2 1 | 1 | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 3 | P2 2, P3 1 | 2 | 0 |
| Aveta Biomics, Inc. | 2 | P2 1, P3 1 | 1 | 1 |
| Beijing Konruns Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| Inhibrx Biosciences, Inc INBX | 2 | P2 1, P3 1 | 0 | 0 |
| Janssen Research & Development, LLC | 2 | P2 1, P3 1 | 0 | 0 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2 | P2 1, P3 1 | 1 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Johnson & Johnson Enterprise Innovation Inc. JNJ | 2 | P3 1, P1 1 | 0 | 0 |
Recently stopped trials
- NCT04428151 Merck Sharp & Dohme LLC - terminated: Business Reasons Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monother
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT03444701 Eisai Co., Ltd. - terminated: The trial was prematurely terminated due to the sponsor's decision. A Study of E7130 in Participants With Solid Tumors
- NCT06091930 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Can
- NCT03881488 Compass Therapeutics - terminated: The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta
- NCT05048368 Sunshine Lake Pharma Co., Ltd. - withdrawn: Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled. Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
- NCT03108495 Iovance Biotherapeutics, Inc. - terminated: After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
- NCT04844073 Takeda - terminated: Sponsor decision based on limited anti-cancer activity of TAK-186. A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
- NCT04630353 AstraZeneca - terminated: Sponsor decision. A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
- NCT07181720 Chongqing Precision Biotech Co., Ltd - suspended: Sponsor stopped the study. CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
- NCT06790966 PDS Biotechnology Corp. - terminated: The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigat Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- NCT04949256 Merck Sharp & Dohme LLC - terminated: Trial was rendered as cancelled work ongoing in the book of business. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Me
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
- NCT05572684 NextCure, Inc. - terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Meta
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05990803 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | Cervical Cancer | recruiting | 130 |
| 2026-12 est. | P1/P2 | Theravectys S.A. | NCT06319963 A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | HPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma | recruiting | 72 |
| 2026-12-27 est. | P2 | Amplexd Therapeutics, Inc. | NCT07572396 Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities | High-risk HPV (Any Strain); LSIL, Low Grade Squamous Intraepithelial Lesion; ASC-US; HPV Infection; | recruiting | 45 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Shanghai Henlius Biotech | NCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | Cervical Cancer; Ovarian Cancer | recruiting | 190 |
| 2026-12-31 est. | P1/P2 | Evopoint Biosciences Inc. | NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Advanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancers | recruiting | 350 |
| 2027-01-31 est. | P2 | Grit Biotechnology | NCT06241781 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2027-01-31 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07202364 A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid | recruiting | 100 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-11 est. | P2 | Precigen, Inc PGEN | NCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metast | recruiting | 24 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "cervical cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.